These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Metabolic syndrome. Part III: its prevention and therapeutic management]. Pacholczyk M; Ferenc T; Kowalski J Postepy Hig Med Dosw (Online); 2008 Oct; 62():559-70. PubMed ID: 18936731 [TBL] [Abstract][Full Text] [Related]
6. [Therapeutic options for metabolic syndrome in obese patients]. Carella AM; Conte M Clin Ter; 2007; 158(5):457-64. PubMed ID: 18062354 [TBL] [Abstract][Full Text] [Related]
7. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Rayner B Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845 [TBL] [Abstract][Full Text] [Related]
8. New treatment strategies for patients with hypertension and insulin resistance. Kurtz TW Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944 [TBL] [Abstract][Full Text] [Related]
9. [ACE inhibitor in metabolic syndrome]. Hasslacher C Z Kardiol; 1994; 83 Suppl 4():21-9. PubMed ID: 7856277 [TBL] [Abstract][Full Text] [Related]
10. The Role of Beta-Blockers in the Treatment of Hypertension. Cruickshank JM Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711 [TBL] [Abstract][Full Text] [Related]
11. [Insulin resistance and arterial hypertension]. Weidmann P; Müller-Wieland D; de Courten M; Krone W Herz; 1995 Feb; 20(1):16-32. PubMed ID: 7713473 [TBL] [Abstract][Full Text] [Related]
12. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Chapman MJ; Sposito AC Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759 [TBL] [Abstract][Full Text] [Related]
13. Utilization of antihypertensive drugs in obesity-related hypertension: a retrospective observational study in a cohort of patients from Southern Italy. Cataldi M; di Geronimo O; Trio R; Scotti A; Memoli A; Capone D; Guida B BMC Pharmacol Toxicol; 2016 Mar; 17():9. PubMed ID: 26980335 [TBL] [Abstract][Full Text] [Related]
14. Management of the metabolic syndrome. Grant RW; Meigs JB Panminerva Med; 2005 Dec; 47(4):219-28. PubMed ID: 16489321 [TBL] [Abstract][Full Text] [Related]
17. Hypertension and insulin resistance. Prichard BN; Smith CC; Sen S; Betteridge DJ J Cardiovasc Pharmacol; 1992; 20 Suppl 11():S77-84. PubMed ID: 1284147 [TBL] [Abstract][Full Text] [Related]
18. The metabolic syndrome and its cardiovascular manifestations. Sánchez-Torres RJ; Delgado-Osorio H Bol Asoc Med P R; 2005; 97(4):271-80. PubMed ID: 16599068 [TBL] [Abstract][Full Text] [Related]